Loading clinical trials...

LUNG INFECTION in ICU (LUNG-I3) | Clinical Trials | Clareo Health

RECRUITING

LUNG INFECTION in ICU (LUNG-I3)

LUNG INFECTION in ICU

NCT06073834•BioMérieux

Summary

objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All the following criteria
•Age 18 years or greater
•Severe ICU patients hospitalized for one of the above diseases:
•* Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (\>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)
•* Severe trauma (level I and II), Injury Severity Score ≥ 25 OR
•* Burn with TBSA over 20%
•NAD \> 0.1 µg/kg/min
•At least 2 SOFA criteria ≥ 2 points

Exclusion Criteria

•Aspiration pneumonia
•Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
•COPD
•Smoke inhalation in burn patients
•Participation in an intervention study
•Pregnant or breastfeeding women
•Immunocompromised patients, defined as
•* patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease
•* hematologic malignancies
•* solid organ transplantation
+3 more criteria

Locations (1)

Hopital Edouard Herriot

Lyon, France

Key Dates

Start Date

December 5, 2023

Primary Completion Date

April 1, 2026

Completion Date

June 1, 2027

Last Updated

February 12, 2025

Enrollment

ESTIMATED participants

Conditions

VAP - Ventilator Associated Pneumonia

Contacts

Jean-François LLITJOS

CONTACT

+33761568397 jeanfrancois.llitjos@biomerieux.com

Marie-Angelique CAZALIS

CONTACT

+33626807839 marie-angelique.cazalis@biomerieux.com

Effect of the Aspiration Care Bundle on Preventing VAP

NCT07138651

VAP - Ventilator Associated PneumoniaCare+3 more

View study

UNKNOWN

Performance Study of Targeted Sequencing Technology for VAP

NCT06035796

VAP - Ventilator Associated Pneumonia

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LUNG INFECTION in ICU (LUNG-I3)

Inclusion Criteria

Exclusion Criteria

Effect of the Aspiration Care Bundle on Preventing VAP

Performance Study of Targeted Sequencing Technology for VAP

Effect of Statin Therapy on Mortality in Patients With Ventilator Associated Pneumonia